Department of Botany, GCU, Lahore, Pakistan.
Lahore College for Women University, Lahore, Pakistan.
Adv Exp Med Biol. 2019;1152:283-292. doi: 10.1007/978-3-030-20301-6_15.
Based on the insights gleaned from decades of research, it seems clear that mechanistic target of rapamycin (mTOR) is an essential signaling node that integrates environmental clues for regulation of cell survival, metabolism and proliferation of the cells. However, overwhelmingly increasing scientific evidence has added a new layer of intricacy to already complicated and versatile signaling pathway of mTOR. Deregulation of spatio-temporally controlled mTOR-driven pathway played contributory role in breast cancer development and progression. Pharmacologists and molecular biologists have specifically emphasized on the identification and development of mTOR-pathway inhibitors. In this chapter we have attempted to provide an overview of the most recent findings related to therapeutic targeting of mTOR-associated mTORC1 and mTORC2 in breast cancer. We have also comprehensively summarized regulation of mTOR and its partners by microRNAs in breast cancer.
基于几十年来的研究洞察，很明显，雷帕霉素靶蛋白（mTOR）是一个重要的信号节点，它整合了环境线索，调节细胞的存活、代谢和增殖。然而，越来越多的科学证据为已经复杂多样的 mTOR 信号通路增加了新的复杂性。时空控制的 mTOR 驱动途径的失调在乳腺癌的发生和发展中起了促进作用。药理学家和分子生物学家特别强调了鉴定和开发 mTOR 途径抑制剂。在这一章中，我们试图提供最新的关于乳腺癌中 mTOR 相关 mTORC1 和 mTORC2 治疗靶点的发现的概述。我们还全面总结了 microRNAs 在乳腺癌中对 mTOR 及其伴侣的调控。
